This bill requires all health insurance policies, including those for small employers and Medicaid, to provide coverage for biomarker testing, which is defined as the analysis of biological samples to identify specific indicators related to diseases or conditions. Coverage is mandated when supported by medical and scientific evidence, including FDA-approved tests and clinical practice guidelines. The bill aims to ensure that biomarker testing is covered for diagnosis, treatment, management, or monitoring of a covered person's condition without any cost-sharing for individuals.

Additionally, the bill establishes strict timelines for prior authorization requests, mandating that decisions be communicated within 72 hours for non-urgent requests and 24 hours for urgent requests. It also ensures that individuals and their healthcare providers have access to clear information regarding the appeals process for any adverse determinations. The provisions are designed to optimize patient care and minimize disruptions, such as unnecessary biopsies, and the act will take effect 90 days after enactment, applying to policies and contracts issued or renewed thereafter.